A Long-term Study of AK102 in Patients With Hypercholesterolemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 796 participants.
Also called NCT04173403
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 796 participants
- Sponsor
- Registry
-
NCT04173403
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04173403. Allocation not applicable; no masking; primary purpose treatment. Start 2019-11-04 (actual); primary completion 2023-02-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Long-term Study of AK102 in Patients With Hypercholesterolemia
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- 450mg AK102
- Intervention (Drug)
- 300mg AK102
- Intervention (Drug)
- 150mg AK102
- Intervention (Drug)
- Statins and/or Ezetimibe
- Lead sponsor
- Akeso
- Collaborator
- AD Pharma (Guangdong)
Record details
- Record id
cardio:ct-nct04173403- Content hash
d129ee7ebb3301cc479703760913f9a858824e7897e39c2ef9e0c2a1c982da16